Filament Health Corp. (FLHLF)

OTCMKTS · Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
Mar 6, 2026, 4:00 PM EST
-99.62%
Market Cap 26.18K
Revenue (ttm) 329.20K
Net Income (ttm) -2.95M
Shares Out 261.79M
EPS (ttm) -0.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 30,000
Average Volume 47,282
Open 0.0001
Previous Close 0.0001
Day's Range 0.0001 - 0.0001
52-Week Range 0.0000 - 0.0399
Beta 0.76
RSI 31.31
Earnings Date Mar 31, 2026

About Filament Health

Filament Health Corp. operates as a clinical-stage natural psychedelic drug development company in Canada. The company’s leading drug candidates comprises PEX010 oral psilocybin, PEX020 oral psilocin, and PEX030 sublingual psilocin. It also develops AEX010 ayahuasca, which is in preclinical stage; and AEX020 monoamine oxidase inhibitor and is in preclinical stage. In addition, the company provides in-house human clinical trials, as well as license technology to drug developers, researchers, and other licensed parties. Filament Health Corp. is h... [Read more]

Sector Healthcare
CEO Benjamin Lightburn
Employees 13
Stock Exchange OTCMKTS
Ticker Symbol FLHLF
Full Company Profile

Financial Performance

In 2024, Filament Health's revenue was 616,678, a decrease of -71.06% compared to the previous year's 2.13 million. Losses were -4.97 million, -6.61% less than in 2023.

Financial numbers in CAD Financial Statements

News

There is no news available yet.